Literature DB >> 22801343

How much tubal factor infertility is caused by Chlamydia? Estimates based on serological evidence corrected for sensitivity and specificity.

Malcolm J Price1, A E Ades, Nicky J Welton, John Macleod, Katy Turner, Ian Simms, Paddy J Horner.   

Abstract

OBJECTIVES: To estimate the proportion of tubal factor infertility (TFI) caused by Chlamydia trachomatis (CT), the etiologic fraction, from a retrospective study of CT antibody prevalence in TFI cases and controls, adjusted for sensitivity and specificity.
METHODS: We use published data on sensitivity and specificity to estimate the performance of assays in (a) women with a previous CT infection without sequelae and (b) women with TFI caused by CT. A model was developed and applied to antibody prevalence in TFI cases and controls from 1 published case-control study to estimate the proportion of TFI caused by CT.
RESULTS: The proportion of TFI episodes that were due to CT infection was estimated to be 45% (credible intervals: 28%, 62%). Models which assume that test sensitivity is higher in women with CT-related TFI than women with previous infection and no sequelae fit the data significantly better than models that assume the same sensitivity in all those previously infected.
CONCLUSIONS: Greater attention needs to be paid to methods for characterizing the performance of CT antibody tests. Serological studies could be given a greater role both in CT etiology and in monitoring the effects of prevention and control programmes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22801343     DOI: 10.1097/OLQ.0b013e3182572475

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  13 in total

Review 1.  Human and Pathogen Factors Associated with Chlamydia trachomatis-Related Infertility in Women.

Authors:  S Menon; P Timms; J A Allan; K Alexander; L Rombauts; P Horner; M Keltz; J Hocking; W M Huston
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

Review 2.  Advancing the public health applications of Chlamydia trachomatis serology.

Authors:  Sarah C Woodhall; Rachel J Gorwitz; Stephanie J Migchelsen; Sami L Gottlieb; Patrick J Horner; William M Geisler; Catherine Winstanley; Katrin Hufnagel; Tim Waterboer; Diana L Martin; Wilhelmina M Huston; Charlotte A Gaydos; Carolyn Deal; Magnus Unemo; J Kevin Dunbar; Kyle Bernstein
Journal:  Lancet Infect Dis       Date:  2018-07-05       Impact factor: 25.071

Review 3.  What Can Serology Tell Us About the Burden of Infertility in Women Caused by Chlamydia?

Authors:  Patrick J Horner; Gloria E Anyalechi; William M Geisler
Journal:  J Infect Dis       Date:  2021-08-16       Impact factor: 5.226

Review 4.  Screening for genital chlamydia infection.

Authors:  Nicola Low; Shelagh Redmond; Anneli Uusküla; Jan van Bergen; Helen Ward; Berit Andersen; Hannelore Götz
Journal:  Cochrane Database Syst Rev       Date:  2016-09-13

5.  Predicting the Probability of Chlamydia Reinfection in African American Women Using Immunologic and Genetic Determinants in a Bayesian Model.

Authors:  Kristin M Olson; William M Geisler; Rakesh K Bakshi; Kanupriya Gupta; Hemant K Tiwari
Journal:  Sex Transm Dis       Date:  2021-11-01       Impact factor: 2.830

6.  C. trachomatis Pgp3 antibody prevalence in young women in England, 1993-2010.

Authors:  Paddy Horner; Kate Soldan; Sueli M Vieira; Gillian S Wills; Sarah C Woodhall; Richard Pebody; Anthony Nardone; Elaine Stanford; Myra O McClure
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

7.  Chlamydia trachomatis Pgp3 Antibody Population Seroprevalence before and during an Era of Widespread Opportunistic Chlamydia Screening in England (1994-2012).

Authors:  Sarah C Woodhall; Gillian S Wills; Patrick J Horner; Rachel Craig; Jennifer S Mindell; Gary Murphy; Myra O McClure; Kate Soldan; Anthony Nardone; Anne M Johnson
Journal:  PLoS One       Date:  2017-01-27       Impact factor: 3.240

8.  Early screening for Chlamydia trachomatis in young women for primary prevention of pelvic inflammatory disease (i-Predict): study protocol for a randomised controlled trial.

Authors:  Jeanne Tamarelle; Anne C M Thiébaut; Bénédicte Sabin; Cécile Bébéar; Philippe Judlin; Arnaud Fauconnier; Delphine Rahib; Layidé Méaude-Roufai; Jacques Ravel; Servaas A Morré; Bertille de Barbeyrac; Elisabeth Delarocque-Astagneau
Journal:  Trials       Date:  2017-11-13       Impact factor: 2.279

9.  Chlamydial Pgp3 Seropositivity and Population-Attributable Fraction Among Women With Tubal Factor Infertility.

Authors:  Gloria E Anyalechi; Jaeyoung Hong; Robert D Kirkcaldy; Harold C Wiesenfeld; Paddy Horner; Gillian S Wills; Myra O McClure; Karen R Hammond; Catherine L Haggerty; Dmitry M Kissin; Edward W Hook; Michael P Steinkampf; Kyle Bernstein; William M Geisler
Journal:  Sex Transm Dis       Date:  2021-03-31       Impact factor: 3.868

10.  Chlamydia trachomatis Pgp3 Antibody Persists and Correlates with Self-Reported Infection and Behavioural Risks in a Blinded Cohort Study.

Authors:  Patrick J Horner; Gillian S Wills; Antoinette Righarts; Sueli Vieira; Daphne Kounali; Dhanraj Samuel; Alan Winston; David Muir; Nigel P Dickson; Myra O McClure
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.